Koeda Yorihiko, Komatsu Takashi, Matsuura Yuki, Morioka Hidemi, Uchimura Yohei, Taguchi Yuya, Tanaka Kentaro, Kawakami Jun, Nakamura Marie, Takahashi Shuko, Takahashi Yuji, Naganuma Yujiro, Endo Hiroshi, Ito Tatsuro, Morino Yoshihiro, Nakamura Motoyuki
Department of Cardiology, Iwate Prefectural Ofunato Hospital, Japan.
Department of Internal Medicine, Iwate Medical University, Japan.
J Arrhythm. 2017 Oct;33(5):488-493. doi: 10.1016/j.joa.2017.06.006. Epub 2017 Jul 31.
BACKGROUND & PURPOSE: We have conducted a retrospective observational study to analyze the correlation between the CHADS score, the modified CHADS-VASc (mCHADS-VASc) score, and the incidence of all-cause death and congestive heart failure (CHF).
The study cohort consisted of 292 consecutive patients with nonvalvular atrial fibrillation (NVAF) admitted to our hospital from 2012 to 2014. Electronic medical records were used to confirm medical history including prior heart failure, hypertension, diabetes, stroke, and coronary disease. A follow-up survey for all-cause deaths and incidence of CHF was carried out from the baseline data to May 2015. We analyzed the correlation between each score and the endpoints using the Kaplan-Meier method and the Cox proportional hazards model.
During the follow up period (mean=1.6 years), 69 all-cause deaths and 58 CHF events occurred in the cohort. There was no significant association between these scores and all-cause death in our CHF cohort. The incidence of CHF significantly increased along with increased CHADS (=0.018) or mCHADS-VASc scores (=0.044). The hazard ratio (HR) for CHF after adjustment for drug treatment was obtained from a Cox proportional hazards model. The HRs for the CHADS and mCHADS-VASc scores were 1.38 (95% CI; 1.13-1.68) and 1.35 (95% CI; 1.24-1.59), respectively.
Calculation of the CHADS and mCHADS-VASc scores in order to evaluate the risk of systemic thromboembolism was useful to predict the onset of CHF, but not all-cause death, in patients with NVAF.
我们开展了一项回顾性观察研究,以分析CHADS评分、改良CHADS-VASc(mCHADS-VASc)评分与全因死亡及充血性心力衰竭(CHF)发生率之间的相关性。
研究队列包括2012年至2014年连续入住我院的292例非瓣膜性心房颤动(NVAF)患者。使用电子病历确认病史,包括既往心力衰竭、高血压、糖尿病、中风和冠心病。从基线数据至2015年5月对全因死亡和CHF发生率进行随访调查。我们使用Kaplan-Meier方法和Cox比例风险模型分析每个评分与终点之间的相关性。
在随访期间(平均=1.6年),队列中发生了69例全因死亡和58例CHF事件。在我们的CHF队列中,这些评分与全因死亡之间无显著关联。CHF的发生率随着CHADS(=0.018)或mCHADS-VASc评分(=0.044)的增加而显著增加。通过Cox比例风险模型获得调整药物治疗后的CHF风险比(HR)。CHADS和mCHADS-VASc评分的HR分别为1.38(95%CI;1.13-1.68)和1.35(95%CI;1.24-1.59)。
计算CHADS和mCHADS-VASc评分以评估系统性血栓栓塞风险,对于预测NVAF患者CHF的发生是有用的,但对全因死亡无用。